Showing results (251-260 of 335) with videos related to
Sort By:
Pageof 34
Cell Metabolism|March 24, 2021
Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunityYao He, Liuhui Fu, Yiping Li, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2014
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculatureRobbert M Spaapen, Michael Y K Leung, Mercedes B Fuertes, et al.Oncotarget|June 26, 2016
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistanceWenxin Zheng, Kinga B Skowron, Jukes P Namm, et al.Immunity|September 2, 2018
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in RadiotherapyYuzhu Hou, Hua Liang, Enyu Rao, et al.Hepatology (Baltimore, Md.)|April 27, 2017
Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier miceYingjie Bian, Zheng Zhang, Zhichen Sun, et al.Nature Biomedical Engineering|February 9, 2021
Prolonged activation of innate immune pathways by a polyvalent STING agonistSuxin Li, Min Luo, Zhaohui Wang, et al.The Journal of Clinical Investigation|February 8, 2005
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responsesYang Wang, Sumit K Subudhi, Robert A Anders, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 19, 2011
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone miceMarcio O Lasaro, Marina Sazanovich, Wynetta Giles-Davis, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis BDongping Xu, Junliang Fu, Lei Jin, et al.Pageof 34